Abstract Objective The CD155/TIGIT axis has attracted considerable interest as an emerging
immune checkpoint with potential applications in cancer immunotherapy. Our research …

The T-cell surface molecule TIGIT is an immune checkpoint molecule that inhibits T-cell
responses, but its roles in cancer are little understood. In this study, we evaluated the role …

CD155/T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a novel type of immune
checkpoint. CD155 is an adhesion molecule that is upregulated during tumor progression …

Objective TIGIT/CD155 has attracted widespread attention as a new immune checkpoint and
a potential target for cancer immunotherapy. In our study, we evaluated the role of …

As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-
based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4+ T cells, CD8+ T …

TIGIT, an immune checkpoint molecule widely expressed on NK cells, activated T cells and
Tregs, has been involved in delivering inhibitory signals through the interaction with PVR …

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a checkpoint receptor that
mediates both T-cell and natural killer (NK)–cell exhaustion in tumors. An Fc-TIGIT fusion …

Immune checkpoint inhibitors (ICIs) have shown unprecedented efficacy in treating many
advanced cancers. Although FDA-approved ICIs have shown promising efficacy in treating …

Background T‐cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif
domain (TIGIT) is an immune checkpoint molecule that suppresses CD8+ T‐cell function in …

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is
an immunosuppressive receptor expressed on the surface of immune cells, suppressing …